サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1786624

融合生検の世界市場

Fusion Biopsy

出版日
ページ情報
英文 277 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.84円
融合生検の世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 277 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

融合生検の世界市場は2030年までに11億米ドルに達する見込み

2024年に7億1,460万米ドルと推定される融合生検の世界市場は、2024～2030年の分析期間にCAGR 6.7％で成長し、2030年には11億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである経直腸生検ルートは、CAGR 5.5%を記録し、分析期間終了時には6億4,090万米ドルに達すると予測されています。経会陰生検ルートセグメントの成長率は、分析期間中CAGR 8.9%と推定されます。

米国市場は推定1億9,470万米ドル、中国はCAGR10.3％で成長予測

米国の融合生検市場は、2024年には1億9,470万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに2億1,630万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4％と6.4％と予測されています。欧州では、ドイツがCAGR 4.4%で成長すると予測されています。

世界の融合生検市場- 主要動向と促進要因のまとめ

融合生検ががん診断に革命をもたらす理由とは？

融合生検は、その優れた精度と疑わしい病変を正確に捉える能力により、がん診断、特に前立腺がんの検出において画期的な進歩を遂げました。経直腸超音波（TRUS）画像のみに依存する従来の生検法とは異なり、融合生検は磁気共鳴画像（MRI）とリアルタイム超音波を統合し、病変の可視化を高め、サンプリング精度を向上させます。この組み合わせにより、偽陰性の結果や不必要な生検の繰り返しのリスクが大幅に減少し、がん診断における長年の課題に取り組むことができます。前立腺がんの罹患率が増加し、早期かつ正確な発見が求められていることから、融合生検は世界中の主要な病院、がんセンター、診断ラボで急速に採用が進んでいます。

従来の生検技術の限界に対するヘルスケア提供者の意識の高まりが、MRI-超音波融合生検の需要をさらに促進しています。臨床医や研究者は、PSA（前立腺特異抗原）値が上昇しているが、標準的なTRUSガイド下生検では決定的な結果が得られない場合に、MRI-超音波検査を使用することを提唱するようになってきています。さらに、画像ソフトウエアやAIを駆使した診断ツールの進歩により、病変の検出精度が向上し、融合生検は腎臓、肝臓、乳房の悪性腫瘍を含む様々ながんの診断ツールとして、より信頼性の高いものとなっています。プレシジョン・メディシンが進化し続ける中、がんの早期発見と個別化治療計画の改善における融合生検の役割は、より顕著になってきています。

テクノロジーはどのように融合生検の精度と効率を高めているのでしょうか？

最近の医療画像と生検技術の革新は、融合生検手技の効率と精度を大幅に改善しました。AIを駆使した画像解析により病変検出機能が強化され、サンプリングエラーのリスクが減少し、診断の信頼性が向上しました。リアルタイムの3D画像は、臨床医が腫瘍の位置を正確にマッピングし、それに応じて針の軌道を調整できるようにすることで、生検プロセスをさらに最適化しています。さらに、ロボット支援生検システムは融合生検プラットフォームと統合され、精度の向上、患者の不快感の最小化、手技時間の短縮を実現しています。

また、クラウドベースの生検管理ソフトウェアの開発により、データの保存、分析、病理医や腫瘍医間の遠隔コラボレーションが効率化されています。これらのデジタルプラットフォームは、生検結果のシームレスな共有を可能にし、集学的がん治療やセカンドオピニオンのコンサルテーションを促進します。さらに、機械学習アルゴリズムの融合生検システムへの統合により、がん組織の自動識別が可能になり、侵襲的な再手術の必要性が減少しています。低侵襲診断技術の採用が拡大し続ける中、融合生検は、しばしば結論が出なかったり信頼性に欠ける結果をもたらす従来の生検法に取って代わり、腫瘍診断における標準的な治療法となることが期待されています。

融合生検の需要を牽引している医療専門分野とヘルスケア機関は？

泌尿器科は依然として融合生検の需要を牽引する主要な医療専門分野であり、前立腺がん診断がそのアプリケーションの大半を占めています。主要な病院、がん専門クリニック、画像診断センターは、患者の転帰を改善し、誤診率を減らすために、融合生検システムに積極的に投資しています。さらに、学術研究機関や臨床試験機関では、融合生検テクノロジーを新しいバイオマーカーの調査や標的療法の評価に活用し、標準的ながん診断以外の用途にも拡大しています。

前立腺がん以外にも、腎臓、肝臓、膵臓腫瘍の検出のために、腎臓学、消化器学、肝臓学で融合生検の採用が拡大しています。乳がん研究もこの技術の恩恵を受けています。マンモグラフィや超音波の所見で結論が出ない場合、融合生検はより正確な組織サンプリングを可能にしています。遠隔医療と遠隔診断の拡大により、以前は専門的な腫瘍学的画像診断が制限されていた恵まれない地域でも、融合生検の専門知識へのアクセスがさらに容易になりました。がん罹患率の上昇と先端診断技術への投資の増加により、複数の医療専門分野における融合生検の需要は急増すると予想されます。

市場成長を促進する主な要因とは？

融合生検市場の成長は、画像技術の進歩、がん罹患率の増加、早期かつ正確な診断の重視の高まりなど、いくつかの要因によってもたらされます。AI支援画像診断やロボット生検システムの普及により、手技効率が向上し、サンプリングエラーの可能性が減少し、患者の転帰が改善しました。さらに、遠隔医療やクラウドベースの診断プラットフォームの拡大により、融合生検は世界中のヘルスケア機関、特に腫瘍学の専門知識の乏しい地域でも利用しやすくなっています。

融合生検デバイスの規制当局による承認や、新しいバイオマーカーの診断プロトコルへの統合も、市場拡大に拍車をかけています。低侵襲がん診断へのシフトと個別化医療への投資の高まりが、融合生検の需要をさらに強化しています。さらに、医療機器メーカー、研究機関、ヘルスケアプロバイダー間の連携により、精度、自動化、AI主導の意思決定を強化する次世代生検システムの開発が加速しています。ヘルスケアシステムががんの早期発見を優先し続ける中、融合生検は将来のプレシジョン・オンコロジーにおいてますます重要な役割を果たすと予想されます。

セグメント

生検ルート（経直腸生検ルート、経会陰生検ルート）;エンドユース（病院エンドユース、診断センターエンドユース、外来治療センターエンドユース）

調査対象企業の例

  • Artemis
  • Biobot Surgical
  • BK Medical
  • D&K Technologies
  • Eigen
  • Esaote
  • Focal Healthcare
  • GE Healthcare
  • Hitachi Medical Systems
  • innoMedicus
  • KOELIS
  • MedCom
  • Medtronic
  • Philips Healthcare
  • Profound Medical
  • Siemens Healthineers
  • SonaCare Medical
  • Toshiba Medical Systems Corporation
  • United Medical Systems
  • UroNav

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP31101

Global Fusion Biopsy Market to Reach US$1.1 Billion by 2030

The global market for Fusion Biopsy estimated at US$714.6 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Transrectal Biopsy Route, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$640.9 Million by the end of the analysis period. Growth in the Transperineal Biopsy Route segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$194.7 Million While China is Forecast to Grow at 10.3% CAGR

The Fusion Biopsy market in the U.S. is estimated at US$194.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$216.3 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Fusion Biopsy Market - Key Trends & Drivers Summarized

Why is Fusion Biopsy Revolutionizing Cancer Diagnostics?

Fusion biopsy has emerged as a groundbreaking advancement in cancer diagnostics, particularly in the detection of prostate cancer, due to its superior accuracy and ability to target suspicious lesions with precision. Unlike traditional biopsy methods, which rely solely on transrectal ultrasound (TRUS) imaging, fusion biopsy integrates magnetic resonance imaging (MRI) with real-time ultrasound to enhance lesion visualization and improve sampling accuracy. This combination significantly reduces the risk of false-negative results and unnecessary repeat biopsies, addressing a long-standing challenge in cancer diagnostics. Given the increasing prevalence of prostate cancer and the need for early and accurate detection, fusion biopsy is rapidly gaining adoption in leading hospitals, cancer centers, and diagnostic laboratories worldwide.

The growing awareness among healthcare providers about the limitations of conventional biopsy techniques has further fueled the demand for MRI-ultrasound fusion biopsy. Clinicians and researchers are increasingly advocating for its use in cases where PSA (prostate-specific antigen) levels are elevated but standard TRUS-guided biopsies yield inconclusive results. Additionally, advancements in imaging software and AI-driven diagnostic tools have enhanced the accuracy of lesion detection, making fusion biopsy a more reliable diagnostic tool for various forms of cancer, including kidney, liver, and breast malignancies. As precision medicine continues to evolve, the role of fusion biopsy in improving early cancer detection and personalized treatment planning is becoming more prominent.

How is Technology Enhancing the Accuracy and Efficiency of Fusion Biopsy?

Recent innovations in medical imaging and biopsy technology have significantly improved the efficiency and accuracy of fusion biopsy procedures. AI-powered image analysis has enhanced lesion detection capabilities, reducing the risk of sampling errors and improving diagnostic confidence. Real-time 3D imaging has further optimized the biopsy process by allowing clinicians to precisely map tumor locations and adjust needle trajectories accordingly. Additionally, robotic-assisted biopsy systems are being integrated with fusion biopsy platforms to increase precision, minimize patient discomfort, and reduce procedure time.

The development of cloud-based biopsy management software has also streamlined data storage, analysis, and remote collaboration among pathologists and oncologists. These digital platforms enable seamless sharing of biopsy results, facilitating multidisciplinary cancer care and second-opinion consultations. Moreover, the integration of machine learning algorithms into fusion biopsy systems is allowing for the automated identification of cancerous tissues, reducing the need for invasive repeat procedures. As the adoption of minimally invasive diagnostic techniques continues to grow, fusion biopsy is expected to become a standard of care in oncological diagnostics, replacing conventional biopsy methods that often yield inconclusive or unreliable results.

Which Medical Specialties and Healthcare Institutions Are Driving Demand for Fusion Biopsy?

Urology remains the primary medical specialty driving demand for fusion biopsy, as prostate cancer diagnosis accounts for the majority of its applications. Leading hospitals, specialty cancer clinics, and diagnostic imaging centers are actively investing in fusion biopsy systems to improve patient outcomes and reduce misdiagnosis rates. Additionally, academic research institutions and clinical trial organizations are utilizing fusion biopsy technology to study new biomarkers and evaluate targeted therapies, expanding its application beyond standard cancer diagnostics.

Beyond prostate cancer, the adoption of fusion biopsy is growing in nephrology, gastroenterology, and hepatology for the detection of kidney, liver, and pancreatic tumors. Breast cancer research is also benefiting from the technology, as fusion biopsy is enabling more precise tissue sampling in cases where mammographic and ultrasound findings are inconclusive. The expansion of telemedicine and remote diagnostics has further facilitated access to fusion biopsy expertise in underserved regions, where specialized oncological imaging was previously limited. With rising cancer incidence rates and increasing investments in advanced diagnostic technologies, the demand for fusion biopsy across multiple medical specialties is expected to surge.

What Key Factors Are Driving Market Growth?

The growth in the fusion biopsy market is driven by several factors, including advancements in imaging technology, increasing cancer incidence rates, and the growing emphasis on early and accurate diagnosis. The widespread adoption of AI-assisted imaging and robotic biopsy systems has improved procedural efficiency, reducing the likelihood of sampling errors and improving patient outcomes. Additionally, the expansion of telemedicine and cloud-based diagnostic platforms has made fusion biopsy more accessible to healthcare institutions worldwide, particularly in regions with limited oncological expertise.

Regulatory approvals for fusion biopsy devices and the integration of new biomarkers into diagnostic protocols are also fueling market expansion. The shift toward minimally invasive cancer diagnostics, coupled with rising investments in personalized medicine, has further strengthened the demand for fusion biopsy. Additionally, collaborations between medical device manufacturers, research institutions, and healthcare providers are accelerating the development of next-generation biopsy systems that enhance precision, automation, and AI-driven decision-making. As healthcare systems continue to prioritize early cancer detection, fusion biopsy is expected to play an increasingly pivotal role in the future of precision oncology.

SCOPE OF STUDY:

The report analyzes the Fusion Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Biopsy Route (Transrectal Biopsy Route, Transperineal Biopsy Route); End-Use (Hospitals End-Use, Diagnostic Centers End-Use, Ambulatory Care Centers End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Artemis
  • Biobot Surgical
  • BK Medical
  • D&K Technologies
  • Eigen
  • Esaote
  • Focal Healthcare
  • GE Healthcare
  • Hitachi Medical Systems
  • innoMedicus
  • KOELIS
  • MedCom
  • Medtronic
  • Philips Healthcare
  • Profound Medical
  • Siemens Healthineers
  • SonaCare Medical
  • Toshiba Medical Systems Corporation
  • United Medical Systems
  • UroNav

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Fusion Biopsy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Prostate Cancer Drives Adoption of Fusion Biopsy for Accurate Diagnosis
    • Advancements in MRI and Ultrasound Integration Technologies Throw the Spotlight on Precision Biopsy Tools
    • Increased Focus on Minimally Invasive and Targeted Diagnostics Supports Growth of Fusion Biopsy Procedures
    • Clinical Evidence Supporting Improved Cancer Detection Rates With MRI/US Fusion Enhances Physician Confidence
    • Surge in Adoption of MRI-Visible Lesion Mapping Enables High-Precision Prostate Sampling
    • Expansion of Urology Clinics and Specialty Diagnostic Centers Fuels Market Access and Adoption
    • Growth in Medicare and Private Reimbursement Coverage Supports Procedural Volume
    • Integration of AI and Image-Guided Navigation Enhances Fusion Biopsy Accuracy and Workflow
    • Rising Demand for Outpatient Biopsy Solutions Promotes Use of Office-Based Fusion Systems
    • Development of Robotic and Semi-Automated Fusion Platforms Supports Standardization of Results
    • Global Awareness Campaigns on Early Detection of Prostate Cancer Encourage Patient Screening
    • Improved Patient Comfort and Reduced Complication Rates Drive Preference for Fusion Over TRUS-Only Biopsies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fusion Biopsy Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Fusion Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Transrectal Biopsy Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Transrectal Biopsy Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Transrectal Biopsy Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Transperineal Biopsy Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Transperineal Biopsy Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Transperineal Biopsy Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Care Centers End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Care Centers End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Ambulatory Care Centers End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Fusion Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Fusion Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Fusion Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Fusion Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION